Borisow Nadja, Paul Friedemann, Dörr Jan
NeuroCure Clinical Research Center and Clinical and Experimental Research Center for Multiple Sclerosis, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Degener Neurol Neuromuscul Dis. 2014 Aug 5;4:111-120. doi: 10.2147/DNND.S48618. eCollection 2014.
Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system. It frequently affects females in their reproductive phase of life. Therefore, family planning, pregnancy, and breastfeeding are important issues in the management of MS, particularly with respect to counseling and drug treatment. This paper reviews currently available data on the outcome of pregnancies in MS patients and the influence of pregnancy on the course of the disease. We give an update on the use of various disease-modifying MS drugs during pregnancy and breastfeeding. In addition to established therapies such as interferon-β, glatiramer acetate, natalizumab, and fingolimod, we also discuss the state of knowledge about new agents such as dimethyl fumarate, teriflunomide, and alemtuzumab in the context of pregnancy and breastfeeding.
多发性硬化症(MS)是一种常见的中枢神经系统炎性脱髓鞘疾病。它经常影响处于生育期的女性。因此,计划生育、妊娠和母乳喂养是MS管理中的重要问题,特别是在咨询和药物治疗方面。本文综述了目前关于MS患者妊娠结局以及妊娠对疾病进程影响的可用数据。我们更新了妊娠和母乳喂养期间各种改变病情的MS药物的使用情况。除了干扰素-β、醋酸格拉替雷、那他珠单抗和芬戈莫德等既定疗法外,我们还讨论了妊娠和母乳喂养背景下富马酸二甲酯、特立氟胺和阿仑单抗等新药的知识状况。